FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-028								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Warner Douglas J  (Last) (First) (Middle)  C/O EFFECTOR THERAPEUTICS, INC.			<u>e</u>	Issuer Name and Ticker or Trading Symbol eFFECTOR Therapeutics, Inc. [ EFTR ]  3. Date of Earliest Transaction (Month/Day/Year) 08/08/2022						(Che	elationship of Reporting Person(s) to Issuer ck all applicable)  Director 10% Owner Cofficer (give title below)  Chief Medical Officer			ner			
142 NOR (Street) SOLANA BEACH (City)	A C		92075 (Zip)	4.	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line	ndividual or Joint/Group Filing (Check Applicable e)  X Form filed by One Reporting Person Form filed by More than One Reporting Person						
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3)  2. Transa Date (Month/D			•	ZA. Deemed Execution Date if any (Month/Day/Yea		Code		r. (A) or		str. 3, 4 and 9	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		i. Ownership Form: Direct D) or Indirect I) (Instr. 4)	t B	. Nature of idirect eneficial wnership nstr. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	perivative Conversion Date Execution Date, Tecurity or Exercise (Month/Day/Year) if any			5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration Date of Secu (Month/Day/Year) Underly Derivati		of Securit Underlyin Derivative	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction	Owne Form: Direct or Ind (I) (Ins	(D)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares	nt (Instr er		1(0)		
Stock Option (Right to Buy)	\$0.8975	08/08/2022		A		618,160		(1)		08/07/2032	Common Stock	618,160	\$0.00	618,160	Г		

## **Explanation of Responses:**

1. The stock option vests 25% on August 8, 2023, and in 36 monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

## Remarks:

/s/ Michael Byrnes, Attorneyin-Fact for Douglas J. Warner

08/08/2022

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.